Reading Tip!
>To get to the fulltext easy, use the library proxy bookmarklet or activate our Pubmed url for the Get it! button!
Categories
- Acta Derm Venereol (8)
- Allergy (2)
- Am J Dermatopathol (1)
- Am J Kidney Dis (1)
- Anal Bioanal Chem (1)
- Anal Chem (1)
- Ann Med (1)
- Arch Dermatol (3)
- Arch Phys Med Rehabil (1)
- Arthritis Res Ther (1)
- Arthritis Rheum (1)
- Australas J Dermatol (1)
- BMC Proc (1)
- Br J Dermatol (50)
- Cell Tissue Res (1)
- Clin Exp Dermatol (2)
- Contact Dermatitis (51)
- Dermatol Clin (3)
- Dermatol Res Pract (1)
- Dermatol Surg (1)
- Disabil Rehabil (1)
- Discov Med (2)
- Drugs Aging (2)
- Eur J Dermatol (10)
- Eur J Immunol (1)
- Exp Dermatol (4)
- Front Immunol (1)
- Genes Immun (1)
- Genet Test Mol Biomarkers (1)
- Hum Mol Genet (1)
- Hum Mutat (1)
- Hum Pathol (1)
- Infect Immun (1)
- Inflamm Bowel Dis (1)
- Int J Dermatol (1)
- Int J Med Microbiol (1)
- Invest Ophthalmol Vis Sci (1)
- J Allergy Clin Immunol (3)
- J Am Acad Dermatol (10)
- J Clin Invest (1)
- J Clin Virol (1)
- J Cutan Pathol (3)
- J Dermatol Sci (2)
- J Dtsch Dermatol Ges (4)
- J Eur Acad Dermatol Venereol (9)
- J Hand Ther (1)
- J Immunol (1)
- J Invest Dermatol (20)
- J Med Genet (1)
- J Strength Cond Res (2)
- JAMA Dermatol (4)
- JNMA J Nepal Med Assoc (1)
- Lab Chip (1)
- Methods Mol Biol (1)
- Mol Vis (1)
- N Engl J Med (1)
- Ned Tijdschr Geneeskd (13)
- Ned Tijdschr Tandheelkd (1)
- Neth J Med (1)
- Occup Environ Med (1)
- Opt Lett (1)
- PLoS One (2)
- Qual Health Res (1)
- Regul Toxicol Pharmacol (2)
- Report (1)
- Sci Transl Med (1)
- Skin Res Technol (2)
- Trials (1)
Archives
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- December 2019
- October 2019
- September 2019
- July 2019
- May 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- August 2018
- April 2018
- February 2018
- January 2018
- July 2017
- June 2017
- March 2017
- February 2017
- August 2016
- July 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- April 2014
- March 2014
- February 2014
- November 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- August 2012
- July 2012
- June 2012
Contributors
Meta
Monthly Archives: October 2019
Interpretability of the Quality Of Life in Hand Eczema Questionnaire (QOLHEQ).
Related Articles |
Interpretability of the Quality Of Life in Hand Eczema Questionnaire (QOLHEQ).
J Invest Dermatol. 2019 Oct 10;:
Authors: Oosterhaven JAF, Ofenloch RF, Schuttelaar MLA
Abstract
The Quality Of Life in Hand Eczema Questionnaire (QOLHEQ) is used to measure impairment of health-related quality of life (HRQoL) in hand eczema. Here, we prospectively studied the interpretability of international QOLHEQ scores at three time points: baseline, after 1-3 days (T1) and after 4-12 weeks (T2). Adult patients with hand eczema completed the QOLHEQ and anchor questions for overall assessment of HRQoL impairment. Interpretability of single scores was assessed at baseline by defining severity bands based on agreement with the anchor questions. Smallest detectable change (SDC) was calculated at T1. Minimally important change (MIC) of improvement was calculated at T2 using three methods: mean cut-off, receiver operating curve (ROC) and 95% limit. N=294 adult patients were included (N=160 males, mean age 44.9). The final proposed severity band of overall QOLHEQ single scores (κ-coefficient of agreement, 0.431) was: not at all, 0-10; slightly, 11-39; moderately, 40-61; strongly, 62-86; very strongly, ≥87. Separate overall severity bands were proposed for males and females, and the four subscales of the QOLHEQ. The SDC in N=166 unchanged patients was 18.6 points. The preferred MIC, obtained with the ROC method was 21.5 points. An overall QOLHEQ score of ≥ 22 is recommended as cut-off for a minimally important, real change.
PMID: 31606350 [PubMed – as supplied by publisher]
Posted in J Invest Dermatol
Comments Off on Interpretability of the Quality Of Life in Hand Eczema Questionnaire (QOLHEQ).